Role of macrophages in tuberculous peritonitis: longitudinal follow-up of 16 continuous ambulatory peritoneal dialysis patients  by CHOW, Kai-Ming et al.
90
Macrophages in tuberculous peritonitis
Role of macrophages in tuberculous peritonitis: longitudinal
follow-up of 16 continuous ambulatory peritoneal dialysis
patients
Kai-Ming CHOW1, Wai-Shan WONG2, Viola Chi-Ying CHOW3, Teresa Yuk-Hwa WONG1, Natalie Pui-
Ha CHAN2, Philip Kam-Tao LI1
1Department of Medicine and Therapeutics; 2Department of Anatomical and Cellular Pathology; 3Department
of Microbiology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong.
Abstract
Objective: Mycobacterium tuberculosis is an intracellular pathogen susceptible to macrophage action,
which also has an important role in peritoneal defense. To explore the peritoneal host defense
mechanism and inflammatory process, we longitudinally followed up 16 cases of continuous
ambulatory peritoneal dialysis complicated by tuberculous peritonitis over the past 9 years in
Prince of Wales Hospital.
Methods: Serial peritoneal fluid cell population was monitored in 16 end-stage renal disease patients
with tuberculous peritonitis.
Results: The mean age of the participants was 53 ± 15 years with a mean peritoneal dialysis
duration of 34 months. Peritoneal fluid lymphocytosis was not evident and their population
contributed to 10% ± 7%, 10% ± 6%, and 9% ± 8% of all leukocytes on day 1, 10, and 20 after
peritonitis, respectively. Of the 16 patients, six had either failed to resume peritoneal dialysis or
died of tuberculous peritonitis, and they were defined as the failure group. Compared with the
success group, referring to those who could pursue peritoneal dialysis, the peritoneal fluid
macrophage cell count percentage was lower in the failure group. Twenty days after tuberculous
peritonitis, the peritoneal fluid macrophage cell count proportion in success and failure groups was
45% ± 11% and 10% ± 10%, respectively (p=0.021). However, polymorphonuclear leukocytes were
more abundant in failure groups as early as 3 days after peritonitis, 93% ± 3% versus 44% ± 12%
in the success group (p=0.003).
 Conclusion: Data in this study support the hypothesis that macrophages represent an important
defense mechanism of the peritoneal cavity against mycobacterial infection and possibly the major
peritoneal inflammatory process.
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INTRODUCTION
Peritoneal inflammation after continuous ambulatory
peritoneal dialysis (CAPD) peritonitis is a tightly
orchestrated sequence of leukocyte activation and
recruitment (1). Inflammation has a pivotal role in
modulating the function and possibly structure of the
peritoneal membrane (2). In view of the close link
between peritoneal inflammation and membrane function
in the peritoneal dialysis population, it is important to
understand this inflammatory process.
Resident peritoneal macrophages represent one of the
major differentiated cells of the mononuclear phagocyte
system, and have been thought to represent the first line
of defense of the peritoneal cavity by virtue of the
phagocytosis and bactericidal capacity (3,4).
Mycobacterium tuberculosis, the causative agent of
tuberculous peritonitis, is an intracellular pathogen that
resides predominantly within macrophages, which are,
in turn, the first line of defense against this pathogen (5,
6). Tuberculous peritonitis in CAPD patients, therefore,
provides a unique opportunity to investigate the roles of
mononuclear phagocytes in the immune response and
host defense of the peritoneal cavity. Analysis of the
cellular characteristics of peritoneal fluid can provide
valuable information about this disease entity and
possibly peritoneal inflammation as a whole.
METHODS
Patient selection
From January 1994 through December 2001, 16
consecutive patients with CAPD complicated by
tuberculous peritonitis were recruited for monitoring.
Clinical data were collected, including demographic
details, coexisting medical problems, clinical course, and
patient and membrane survival information as of April
1, 2002.
Cellular composition of peritoneal fluid was serially
monitored every 3 to 5 days throughout the course of
tuberculous peritonitis. An aliquot of the effluent was
recovered, after a dwell time of at least 4 hours, for
determination of total white cell count and differential
count. Morphologic identification of the various cell
types was performed after centrifuging and staining the
peritoneal fluid sample, within 3 to 5 hours of storage in
sample tubes containing ethylenediamine tetraacetic acid.
The cell count profiles were taken as a crude surrogate
of cell recruitment. No immunophenotypic and
cytochemical analyses were performed.
All patients with a diagnosis of tuberculosis peritonitis
received a standard combination treatment protocol
including isoniazid, rifampicin, pyrazinamide, and a
fourth agent (either ethambutol or streptomycin). The
policy of removing the Tenckhoff catheter (7) was at the
discretion of physicians; all removals were followed by
attempted reinsertion.
Patients were divided into two groups based on the
clinical outcome. Success group referred to those who
could be maintained on or resumed peritoneal dialysis
after temporary cessation of CAPD. The failure group
consisted of patients who died of tuberculous peritonitis
and those for whom reimplantation of Tenckhoff
catheters failed, both of which serve as markers of severe
peritoneal inflammation.
Statistics
Data analysis was performed by using SPSS for Windows
version 9.0 (SPSS Inc., Chicago, IL). Results were
expressed as mean ± standard deviation unless otherwise
stated. Data were compared by chi-square test, Fisher’s
exact test, or Mann-Whitney U test where appropriate.




Among the patients undergoing CAPD, 16 cases of
tuberculous peritonitis were identified. There were eight
men and eight women, with a mean age of 53 ± 15 years
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(range, 31-72 years). On average, they had received
peritoneal dialysis for 34 months before they developed
tuberculous peritonitis.
In seven (44%) cases, Tenckhoff catheters were removed
before completion of the therapy. Subsequent attempted
reinsertion of peritoneal dialysis catheters in three of
them was abandoned because of dense peritoneal
adhesion. Another three patients failed to pursue
peritoneal dialysis simply because they died of severe
tuberculous peritonitis episodes. These six cases were
regarded as failure group.
For the remaining 10 cases who were maintained on
peritoneal dialysis (success group), two of them required
additional 2-L peritoneal exchanges subsequently.
Peritoneal cell counts and outcomes
The effluent leukocytes from CAPD patients increased
after tuberculous peritonitis. The overall white blood
cell differentiation upon presentation was 63%
polymorphonuclear leukocytes (range, 13%-95%), 10%
lymphocytes (range, 0%-25%), 28% mononuclear
macrophages (range, 0%-68%), and 2% eosinophils
(range, 0%-11%). In general, polymorphs predominated
in the peritoneal fluid compared with the lymphocyte
population throughout the clinical course (Fig. 1). The
percentages of lymphocytes were 10% ±  7%, 10% ±
6%, and 9% ± 8% of all leukocytes on day 1, 10, and 20
after peritonitis, respectively.
Table 1 describes the demographic characteristics and
clinical features between the two groups of patients with
different outcomes. No difference was noted between
the baseline characteristics among the success (n = 10)
and failure groups (n = 6), apart from increased likelihood
of Tenckhoff catheter removal in the failure group.
Otherwise, the difference in outcome was not related to
the comorbidity, duration of peritoneal dialysis, or
previous CAPD peritonitis episodes.
The proportion of mononuclear macrophage cells of all
leukocytes tended to be lower in the failure group (Fig.
2), and so did the absolute concentration of macrophages
(not shown). The difference in the macrophage peritoneal
Figure 1. Trend of peritoneal fluid polymorphonuclear leukocytes
and lymphocytes.
Table 1. Demographic characteristics of the success and failure groups.
Success (n = 10) Failure (n = 6) p value
Sex (M/F) 5:5 3:3 1.00*
Age, years 56 ± 15 52 ± 16 0.61†
Duration of peritoneal dialysis, months 38 ± 42 28 ± 34 0.79‡
Episode(s) of previous CAPD peritonitis 1.1 ± 1.3 1.7 ± 0.4 0.06†
Coexisting diseases (%)
  Diabetes mellitus 3 (30) 3 (50) 0.61*
  Corticosteroid therapy 1 (10) 1 (17) 1.00*
  Cirrhosis 1 (10) 0 1.00*
  Hepatitis B surface antigen 2 (20) 2 (33) 0.60*
  Malignancy 3 (30) 0 0.25*
  Hemoglobin level, g/dL 8.6 ± 2.9   8.4 ± 1.7 0.88†
Concurrent tuberculosis (%)
  Pulmonary 1 (10) 3 (50) 0.12*
  Extrapulmonary 3 (30) 2 (33) 1.00*
Diagnosed cases in life (%) 10 (100) 5 (83) 0.38‡
Treatment within 6 weeks (%) 6 (60) 3 (50) 1.00*
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population between the success and failure groups
reached statistical significance only by day 20 of
peritonitis. Mononuclear macrophages sampled at day
20 contributed to 45 ± 11% of all peritoneal fluid
leukocytes in the success group and 10% ± 10% in failure
group respectively (p=0.021). A greater degree of
peritoneal polymorph dominance occurred in the failure
group than the success group (Fig. 3), but there was only
a significant difference at Day 3 of tuberculous
peritonitis, with 93% ± 3% in the former versus 44% ±
12% in the latter group (p=0.003).
DISCUSSION
This study confirms earlier findings (7-11) that peritoneal
fluid lymphocytosis is not characteristic of tuberculous
peritonitis, as opposed to what had once been thought to
be true (12,13). More importantly, findings of the patients
in this study with tuberculous peritonitis on dialysis
therapy facilitate us to explore the role of mononuclear
phagocytes in the immune response and host defense of
the peritoneal cavity.
Significant recent advances have been made in
understanding the mechanisms by which local peritoneal
defense mechanisms and cell-mediated immune response
prevent and eradicate peritoneal infection. It is now
recognized that all three main cell systems operate in
the peri toneal  cavity,  namely,  macrophages,
lymphocytes, and mesothelium, acting against invasion
of microorganism (14). Among them, macrophages
provide the first-line host defense via phagocytic activity
and production of inflammatory cytokines.
Instead of performing sophisticated in vivo or in vitro
experiments as have been done by previous investigators
(15-17), we made an effort to correlate the peritoneal
leukocyte profiles and measurable clinical outcomes. In
such case, the clinical outcome(s) examined needs to be
of biologic and practical relevance. Clearly, mortality
from peritonitis and intraperitoneal adhesion precluding
resumption of CAPD are well-recognized sequelae of
the inflammatory process with clinical bearing. It was
therefore reasonably valid to use them as tools to define
the failure group in this study. Because we have
demonstrated that lower macrophage population predated
subsequent patient death and/or peritoneal failure from
tuberculous peritonitis, it would suggest a link between
macrophages and inflammation. Aside from resident
macrophages (4,15,16,18) inside or within the
peritoneum membrane, macrophages from delayed
recruitment from systemic circulation are implicated in
this study.
How can a role for polymorphonuclear cells then be
reconciled with the lack of the association with peritoneal
integrity or patient survival in this study? Evidence has
long existed that activated macrophages, rather than
neutrophils, mediate the key intracellular mycobacterial
killing mechanisms (5,19). In other words, the defense
mechanism in the failure group from this study was
presumably upregulated, but only via an ineffective
pathway, as characterized by an influx and activation of
neutrophils at the site of infection. The polymorphonuclear
immune response (20) is therefore incapable of
eradicating intracellular mycobacteria and poorly
targeted, leading to indiscriminate tissue (peritoneal)
damage.
One criticism of our reporting leukocyte cell counts alone
is that the qualitative state of each leukocyte class could
not be addressed. The ability of different macrophage
phenotypes to produce cytokines, besides chemotactic
and phagocytic capacity (17), is thus ignored.
Although we evaluated the effect of macrophage
recruitment on adverse outcomes (patient mortality and
peritoneal failure), it may be important (21) to correlate
Figure 2. Proportion of peritoneal mononuclear macrophages.
Figure 3. Proportion of peritoneal polymorphonuclear leukocytes.
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the macrophage defense with subsequent peritoneal
membrane function (permeability and ultrafiltration
volume) after recovery from tuberculous peritonitis.
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